Predictive factors for the achievement of DAS28-CRP remission at the end of the re-treatment period*
| Baseline parameter | OR (95% CI) | P value |
| Treatment | ||
| Abatacept†+MTX vs MTX | 1.71 (0.63 to 4.63) | 0.6923 |
| Abatacept vs MTX | 2.07 (0.74 to 5.77) | 0.3026 |
| DAS28-CRP | 0.80 (0.44 to 1.47) | 0.4727 |
| SJC (28 joints) | 1.00 (0.96 to 1.05) | 0.9271 |
| PtGA (0–100 mm VAS) | 0.97 (0.94 to 1.00)† | 0.0199 |
| Baseline corticosteroid use (yes vs no) | 1.34 (0.55 to 3.28) | 0.5219 |
| RA symptom duration (<3 vs ≥3 months) | 1.08 (0.44 to 2.66) | 0.8634 |
| Smoking status (yes‡ vs no) | 1.16 (0.49 to 2.79) | 0.7346 |
| Anti-CCP2 (positive vs negative)§ | 1.62 (0.69 to 3.80) | 0.2730 |
ORs and p values were based on an adjusted logistic regression model including the following baseline parameters: randomised treatment, DAS28-CRP, SJC, PtGA, corticosteroid use, RA symptom duration, smoking status and anti-CCP2 antibody status.
*All randomised and treated patients who entered the withdrawal period.
†Due to rounding, the upper 95% CI value of 0.995 is shown as 1.00.
‡Includes previous and current smokers.
§At the end of the treatment period, respectively, 8/98 (8%), 1/85 (1%) and 1/94 (1%) of patients treated with abatacept+methotrexate, abatacept and methotrexate became anti-CCP2 seronegative.
Anti-CCP2, anticyclic citrullinated peptide 2; DAS28-CRP, Disease Activity Score 28-C reactive protein; MTX, methotrexate; PtGA, Patient Global Assessment of Disease Activity; RA, rheumatoid arthritis; SJC, swollen joint count; VAS, Visual Analogue Scale.